GTx competitors

GTx Competitors include Rexahn Pharmaceuticals, Burzynski Research Institute, Alpine Immune Sciences and Syndax Pharmaceuticals.
Add company...
GTx
GTx
GTx, Inc is a pharmaceutical company and developer of drugs that utilize hormonal pathways.
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.
Burzynski Research Institute
Burzynski Research Institute
Burzynski Research Institute is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer.
Alpine Immune Sciences
Alpine Immune Sciences
Modern therapies targeting the immune synapse.
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.
Founding Date
Founding Date
1997
Founding Date
2001
Founding Date
1984
Founding Date
2015
Founding Date
2005
Type
Type
Public
Type
Public
Type
Public
Type
Private
Type
Public
Tags
Locations
Locations
Memphis, US HQ
Locations
Rockville, US HQ
Locations
Houston, US HQ
Stafford, US
Locations
Seattle, US HQ
Locations
Waltham, US HQ
Employees
Employees
274% increase
Employees
1715% decrease
Employees
2
Employees
N/A
Employees
4438% increase
Valuation ($)
Valuation ($)
23.1 m
Valuation ($)
51.8 m
Valuation ($)
4 m
Valuation ($)
N/A
Valuation ($)
150 m
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
166
Twitter followers
108

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$1.7m (FY, 2017)
Revenue (est.)
$2.1m (FY, 2017)
Net income
Net income
($30.4m) (FY, 2017)
Net income
($25.3m) (FY, 2017)
Net income
($1.6m) (FY, 2018)
Net income
($7.8m) (FY, 2017)
Net income
($60.8m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 64.7m
Total funding raised
$ 5m
Total funding raised
N/A
Total funding raised
$ 49.3m
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Rexahn Pharmaceuticals
HQ
Rockville, US
Employees
17↓ 15% decrease

Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.

View company
Burzynski Research Institute
HQ
Houston, US
Employees
2

Burzynski Research Institute is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer.

View company
Alpine Immune Sciences
HQ
Seattle, US

Modern therapies targeting the immune synapse.

View company
Syndax Pharmaceuticals
HQ
Waltham, US
Employees
44↑ 38% increase

Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.

View company